<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809636</url>
  </required_header>
  <id_info>
    <org_study_id>59270</org_study_id>
    <nct_id>NCT04809636</nct_id>
  </id_info>
  <brief_title>Evaluating the Impact of Incentives on Clinical Trial Participation</brief_title>
  <official_title>Evaluating the Impact of Incentives on HIV Related Clinical Trial Participation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Riverside</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Riverside</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the impact of incentives on clinical trial&#xD;
      participation. 1) characterize key stakeholders' views on and assessment of incentives, 2)&#xD;
      reach consensus among stakeholders on the factors to be considered when choosing incentives&#xD;
      and their relative importance, 3) pilot test using vignettes for incentive decision making.&#xD;
      We hypothesize that potential study participants make trade-offs regarding the&#xD;
      characteristics of a research study when deciding whether to volunteer. This amendment is to&#xD;
      document IRB reliance between UCR and USF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>characterize how people living with HIV assess incentives</measure>
    <time_frame>3 months</time_frame>
    <description>we will conduct a 20 question quantitative survey of a nationally representative sample of people living with HIV asking about specific study payment information and scenarios</description>
  </primary_outcome>
  <primary_outcome>
    <measure>characterize key stakeholders' views on and assessment of incentives</measure>
    <time_frame>3 months</time_frame>
    <description>focus groups, and key informant interviews will be used to characterize key stakeholders' (people aging with HIV, IRB members, researchers) views on and assessment of incentives, with qualitative analysis of text done using RaDAR. We will use Conjoint Analysis (CJA) to estimate the relative importance (also called &quot;weight&quot;) that participants place on each study characteristic when choosing between different hypothetical studies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pilot testing vignettes for incentive decision making</measure>
    <time_frame>3 months</time_frame>
    <description>We will develop HIV related vignettes (hypothetical scenarios) utilizing the data from outcomes 1 and 2. Specifically, once we have 6 to 8 study characteristics from Aim 2, and the final number of choices (2 - 3) per characteristic, we will use a factorial design to create 25 vignettes (hypothetical scenarios). Individuals from each group (i.e., study participants, researchers, and IRB members) will select the most appropriate incentive from a list of possibilities based on various scenarios. These vignettes will be based on studies identified in the literature and a review of consent forms and created in conjunction with the external advisory board (including pre-testing and revision prior to finalization).</description>
  </primary_outcome>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Hiv</condition>
  <condition>Aging</condition>
  <condition>Incentives</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This is not an interventional study</intervention_name>
    <description>While this is not an intervention, there will be separate participants for the survey study and for the other components of the study (focus groups, interviews, conjoint analysis, piloting the vignettes</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We will recruit patient partners, biomedical HIV researchers and IRB members/bioethicists&#xD;
        involved in HIV research and patient partners with HIV co-morbidities (depression, heart&#xD;
        disease, arthritis). For the patient populations, we will target men (including MSM) and&#xD;
        women aging with HIV, cis and transgender women, and youth (age 18+) of color, but&#xD;
        participation will be open to everyone over 18 years of age living with HIV who speaks&#xD;
        English and live in the United States.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  people living with HIV&#xD;
&#xD;
          -  biomedical HIV researchers&#xD;
&#xD;
          -  IRB members/bioethicists involved in HIV research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  people under 18 years of age&#xD;
&#xD;
          -  people living outside of the United States&#xD;
&#xD;
          -  people who do not speak English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC Riverside</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Davis</last_name>
      <phone>951-827-5733</phone>
      <email>christine.davis@medsch.ucr.edu</email>
    </contact>
    <investigator>
      <last_name>Brandon Brown, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Polonijo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hiv</keyword>
  <keyword>aging</keyword>
  <keyword>incentives</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

